Abstract:In this review, several common types of RNA modifications are reviewed, and the role of regulatory factors related to these modifications in cancer progression is discussed. Finally, the latest advances in small molecule inhibitors of these regulatory factors are especially reviewed. RNA methylation is widespread in nature. Abnormal expression of proteins associated with RNA methylation is strongly associated with a number of human diseases including cancer. Increasing evidence suggests that targeting RNA methylation holds promise for cancer treatment. This review specifically describes several common RNA modifications, such as the relatively well‐studied N6‐methyladenosine, as well as 5‐methylcytosine and pseudouridine (Ψ). The regulatory factors involved in these modifications and their roles in RNA are also comprehensively discussed. We summarise the diverse regulatory functions of these modifications across different types of RNAs. Furthermore, we elucidate the structural characteristics of these modifications along with the development of specific inhibitors targeting them. Additionally, recent advancements in small molecule inhibitors targeting RNA modifications are presented to underscore their immense potential and clinical significance in enhancing therapeutic efficacy against cancer. Key Points In this paper, several important types of RNA modifications and their related regulatory factors are systematically summarised. Several regulatory factors related to RNA modification types were associated with cancer progression, and their relationships with cancer cell migration, invasion, drug resistance and immune environment were summarised. In this paper, the inhibitors targeting different regulators that have been proposed in recent studies are summarised in detail, which is of great significance for the development of RNA modification regulators and cancer treatment in the future.

RNA epigenetics in pulmonary diseases: Insights into methylation modification of lncRNAs in lung cancer

Long non‑coding RNAs: novel links in respiratory diseases (review).

Emerging role of N6-methyladenosine RNA methylation in lung diseases

Non-coding RNA Methylation Modifications in Hepatocellular Carcinoma: Interactions and Potential Implications

A review of current developments in RNA modifications in lung cancer

Comprehensive Analyses of Molecular Features, Prognostic Values, and Regulatory Functionalities of M6a-Modified Long Non-Coding RNAs in Lung Adenocarcinoma.

Role of Main RNA Modifications in Cancer: N6-methyladenosine, 5-Methylcytosine, and Pseudouridine

Research Advances of M6a Modification in Lung Cancer

Emerging role of RNA modification and long noncoding RNA interaction in cancer

RNA methylation and breast cancer: insights into m6A, m7G and m5C

Emerging Roles of RNA Methylation in Gastrointestinal Cancers

Insights into the Role of Long Non-Coding RNAs in DNA Methylation Mediated Transcriptional Regulation

Critical Roles and Clinical Perspectives of RNA Methylation in Cancer

DNA methylation in pulmonary fibrosis and lung cancer

LncRNA-mediated DNA methylation: an emerging mechanism in cancer and beyond

RNA m6A methylation regulators in liver cancer

The Diverse Role of RNA Methylation in Esophageal Cancer

RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy

The role of RNA methylation in tumor immunity and its potential in immunotherapy

Dna Methylation And Nonsmall Cell Lung Cancer

N6-methyladenosine Modification of Noncoding RNAs: Mechanisms and Clinical Applications in Cancer